Overview

A Multi-Center Study Evaluating the Onset and Duration of Action of AC-170 0.24% Compared to Vehicle in the Conjunctival Allergen Challenge (CAC)

Status:
Completed

Trial end date:
2012-06-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate the onset and duration of action of AC-170 0.24% compared to vehicle in the prevention of the signs and symptoms of allergic conjunctivitis in the conjunctival allergen challenge (CAC) model.

Phase:

Phase 3

Details

Lead Sponsor:

Aciex Therapeutics, Inc.

Treatments:

Cetirizine